Moxifloxacin and gemifloxacin mediates its antispasmodic profile via ATP-sensitive potassium channels: An in-vitro bioassay study

Pak J Pharm Sci. 2021 Sep;34(5(Supplementary)):1983-1988.

Abstract

Moxifloxacin and gemifloxacin were tested on isolated rabbits' jejunal preparations as little is known about its effects on gastrointestinal tissues. Moxifloxacin and gemifloxacin were tested in concentrations 0.01-10μg/mL for possible effect(s) on isolated rabbits' jejunal preparations. The drugs were applied on spontaneous, on low K+ (20mM)-induced contractions and on high K+ (80mM)-induced contractions. Response was plotted as % of its respective controls. EC50 for Moxifloxacin and Gemifloxacin on spontaneous (without Glibenclamide) contractions are 2.83±0.5μg/mL and 1.11±0.2μg/mL, respectively. Moxifloxacin and Gemifloxacin relaxed the low K+ (20mM) -induced contractions, which were inhibited in presence of Glibenclamide (3μM). Our result indicates that the relaxant activity of Moxifloxacin and Gemifloxacin is mediated possibly through activation of ATP-sensitive potassium channels (KATP). The relaxant effect of Moxifloxacin and Gemifloxacin is predominantly mediated by activation of ATP-Sensitive potassium channels (KATP), which could be cause of one of relaxing mechanisms.

MeSH terms

  • Animals
  • Biological Assay
  • Female
  • Gemifloxacin / pharmacology*
  • Glyburide / pharmacology
  • Jejunum / drug effects
  • KATP Channels / drug effects*
  • Male
  • Moxifloxacin / pharmacology*
  • Muscle Contraction / drug effects
  • Muscle Relaxants, Central / pharmacology
  • Muscle Relaxation / drug effects
  • Parasympatholytics / pharmacology*
  • Rabbits

Substances

  • KATP Channels
  • Muscle Relaxants, Central
  • Parasympatholytics
  • Gemifloxacin
  • Glyburide
  • Moxifloxacin